A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb®541 in Advanced Solid Tumors Read more
A First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Patients With Advanced Solid Tumors Read more
An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer Read more
A First-In-Human, Phase 1, Open-Label, Multicenter Study of ZW251, a Novel Glypican-3 Targeting Antibody-Drug Conjugate, in Participants with Advanced Solid Tumors, Including Hepatocellular Carcinoma Read more
Identification of Novel Metabolomics and MRI Based Biomarkers Predictive of Early Radiation Induced Cardiac Toxicity Following Treatment for Thoracic Malignancies Read more
Phase III randomized and double-blinded trial of de-escalated radiation in FMISO PET-selected good risk versus standard of care radiation in unselected HPV positive oropharyngeal cancer Read more
Determining the proportion of Cancer Center patients with certain diagnoses over the last two years who would be eligible for treatment with RefleXion Scintix technology. Read more
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma Read more
